Frontline Osimertinib Approved in China for EGFR+ NSCLC

Sep 4, 2019 – China’s National Medical Products Administration has approved osimertinib for the frontline treatment of adult patients with locally-advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitutions. The approval is based on the phase III FLAURA trial , in which frontline osimertinib reduced the risk of progression or death by 54% versus standard TKI therapy – erlotinib or gefitinib. In the … (leggi tutto)